Methodological Issues in Clinical Drug Development for Essential Tremor

Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET...

Descripción completa

Detalles Bibliográficos
Autores principales: Carranza, Michael A., Snyder, Madeline R., Elble, Rodger J., Boutzoukas, Angelique E., Zesiewicz, Theresa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia University Libraries/Information Services 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570037/
https://www.ncbi.nlm.nih.gov/pubmed/23440401
Descripción
Sumario:Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.

Ejemplares similares